Everolimus + Mycophenolate mofetil + Everolimus
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Cardiac Transplantation
Conditions
Cardiac Transplantation
Trial Timeline
Sep 1, 2009 → Dec 1, 2013
NCT ID
NCT01017029About Everolimus + Mycophenolate mofetil + Everolimus
Everolimus + Mycophenolate mofetil + Everolimus is a approved stage product being developed by Novartis for Cardiac Transplantation. The current trial status is completed. This product is registered under clinical trial identifier NCT01017029. Target conditions include Cardiac Transplantation.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01017029 | Approved | Completed |
Competing Products
20 competing products in Cardiac Transplantation